Probenecid for use in treating epileptic diseases, disorders or conditions

Patent metadata

Field	Value
Publication number	US-2025288544-A1
Application number	US-202519223794-A
Country	US
Kind code	A1
Filing date	May 30, 2025
Priority date	Jul 13, 2017
Publication date	Sep 18, 2025
Grant date	—

Abstract

Probenecid or a pharmaceutical acceptable salt thereof for use in the treatment of a neurological disorder in a subject in need thereof, wherein administration of probenecid or a pharmaceutical acceptable salt thereof controls clinical or electrographic seizures in the subject. Preferably, the neurological disorder is an epileptic disease, disorder or condition.

First claim

1 . A method for inducing a decrease of the frequency and/or duration of spontaneous seizures in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of probenecid or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein said subject suffers from focal epilepsy and wherein said seizures are focal seizures.

3 . A method for controlling clinical or electrographic seizures in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of probenecid or a pharmaceutically acceptable salt thereof.

4 . The method of claim 3 , wherein said subject suffers from focal epilepsy and wherein said seizures are focal seizures.

5 . A method for treating epilepsy in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of probenecid or a pharmaceutically acceptable salt thereof.

6 . The method according to claim 5 , wherein administration of probenecid or the pharmaceutical acceptable salt thereof controls epileptic seizures in said subject.

7 . The method according to claim 5 , wherein said epilepsy is focal epilepsy.

8 . The method according to claim 5 , wherein said epilepsy is selected from the group consisting of familial epilepsy, genetic epilepsy, structural/metabolic epilepsy and epilepsies with unknown cause.

9 . The method according to claim 5 , wherein said epilepsy is brain tumor-related epilepsy.

10 . The method according to claim 5 , wherein said epilepsy is a malformation of cortical development (MCD)-related epilepsy.

11 . The method according to claim 5 , wherein said epilepsy is a neurodegenerative-related epilepsy.

12 . The method according to claim 5 , wherein said epilepsy is a dysimmune epilepsy.

13 . The method according to claim 5 , wherein said subject is suffering from a treatment-resistant epilepsy.

14 . The method according to claim 5 , wherein said subject is a child.

15 . The method according to claim 5 , wherein said subject is an adult.

16 . The method according to claim 5 , wherein probenecid or the pharmaceutical acceptable salt thereof is administered to the subject at a dose ranging from 1 mg/kg/day to 100 mg/kg/day.

17 . The method according to claim 5 , wherein probenecid or the pharmaceutical acceptable salt thereof is administered orally.

18 . The method according to claim 5 , wherein probenecid or the pharmaceutical acceptable salt thereof is administered by injection.

Assignees

• Paris Sciences Lettres Quartier Latin
• Centre Nat Rech Scient
• Inst Nat Sante Rech Med
• Univ Sorbonne
• Aphp Assist Publique Hopitaux De Paris
• Commissariat A L’Energie Atomique Et Aux Energies Alternatives Cea
• Univ Paris

Inventors

• Rouach Nathalie
• Dossi Eléna
• Huberfeld Gilles

Classifications

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61K31/195 Primary

  having an amino group · CPC title